10-K: NKGen Biotech Releases Code of Business Conduct and Ethics and Files 10-K Annual Report

NKGen Biotech, Inc. has released its Code of Business Conduct and Ethics and filed its 10-K annual report, outlining its commitment to ethical practices and providing a detailed overview of its financial performance and business activities.

Summary

• NKGen Biotech has adopted a Code of Business Conduct and Ethics, emphasizing honesty, legal compliance, and ethical behavior for all employees, officers, and directors.
• The company's 10-K filing details a merger transaction on September 29, 2023, where Graf Acquisition Corp. IV became NKGen Biotech, Inc.
• The merger involved an exchange ratio of 0.408, resulting in 15,595,260 shares of NKGen common stock issued for Legacy NKGen common stock.
• NKGen received approximately $21.9 million in gross proceeds from the merger, with an additional $32.9 million held in escrow.
• The company is developing cell therapies for neurodegenerative and oncological diseases, focusing on activated NK cells.
• Their proprietary process produces SuperNK (SNK) cells, which have shown increased activity compared to the starting population of NK cells.
• The company is advancing clinical development of SNK01 in Alzheimer's disease (AD) and Parkinson's disease (PD), and SNK02 in solid tumors.
• NKGen owns and operates a 25,000 sq. ft. drug manufacturing facility in Santa Ana, California, equipped for GMP production of NK cells.
• As of December 31, 2023, the company had approximately 63 full-time employees.
• The company has a license agreement with NKMAX, granting exclusive rights to develop and commercialize NK cell therapies in all countries excluding Asia.
• The company has incurred substantial transaction expenses in connection with the Business Combination and has a working capital deficit of approximately $37.5 million as of December 31, 2023.
• The company's independent registered public accountants and management have expressed substantial doubt as to the company's ability to continue as a going concern without additional capital.

Sentiment

Score: 4

Explanation: The document highlights promising technology and clinical progress, but is overshadowed by significant financial concerns and the company's going concern status. The risk factors are substantial, leading to a negative sentiment overall.

Positives

• The company has a proprietary manufacturing process for SNK cells that addresses key limitations of other NK cell therapies.
• SNK cells have demonstrated increased activity, cryopreservation capabilities, and scalability.
• The company has initiated clinical trials for SNK01 in AD and PD, showing promising early results.
• NKGen has a GMP manufacturing facility, enabling in-house production of NK cell therapies.
• The company has established strategic collaborations to accelerate development in oncology.

Negatives

• The company has a significant working capital deficit of approximately $37.5 million as of December 31, 2023.
• The company's independent registered public accountants and management have expressed substantial doubt as to the company's ability to continue as a going concern without additional capital.
• The company has incurred substantial transaction expenses in connection with the Business Combination.
• The company has a limited operating history and has incurred significant losses since its inception.
• The company has never generated revenue from product sales and may never achieve or maintain profitability.

Risks

• The company currently does not have sufficient funds to service its operations and requires additional capital.
• The company's business depends upon the success of its NK cell therapy platform, which is a novel approach with significant challenges.
• Clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company may fail to develop its product candidates successfully or may be unable to obtain regulatory approval for them.
• The company has never commercialized a product candidate before and may lack the necessary expertise and resources.
• The company's manufacturing process is novel and complex, and they may encounter difficulties in production.
• The company's license agreement with NKMAX is critical, and its termination could impact their ability to develop their NK cell technology platform.
• The company may be unable to maintain the listing of its securities on Nasdaq in the future.
• The company's stock price may be volatile and may decline regardless of its operating performance.

Future Outlook

The company intends to advance clinical development of SNK01 in AD and PD, and SNK02 in solid tumors, while also exploring strategic collaborations and investing in manufacturing technology. The company also intends to submit an IND to the FDA to conduct a Phase I trial in PD.

Management Comments

• The company is committed to maintaining the highest standards of business conduct and ethics.
• The company believes that SNK cells have the potential to deliver transformational benefits to patients with both neurodegenerative and oncological diseases.
• The company is focused on optimizing parameters that are critical for NK cell therapy to drive clinical and commercial success.

Industry Context

The biotechnology industry, particularly the cell therapy field, is characterized by rapid advancements, intense competition, and a strong emphasis on intellectual property. NKGen faces competition from major pharmaceutical, specialty pharmaceutical, and emerging biotechnology companies, as well as academic research institutions.

Comparison to Industry Standards

• NKGen competes with companies like Acepodia, Artiva, Celularity, Century Therapeutics, Cytovia Therapeutics, Fate Therapeutics, Nkarta, and ImmunityBio, all of which have clinical-stage allogeneic programs.
• Other competitors, such as Affimed, Innate Pharma, Dragonfly Therapeutics and GT Biopharma, are seeking to harness NK biology through cell engagers.
• Unlike many competitors, NKGen has a proprietary manufacturing process for SNK cells that addresses key limitations of other NK cell therapies.
• NKGen's focus on both neurodegenerative and oncological diseases sets it apart from some competitors that focus on a single therapeutic area.
• The company's ability to produce hundreds of thousands of doses of allogeneic SNK cells from a single donor is a key differentiator.

Related Party Transactions

• The company has entered into related party loans with NKMAX.
• The company has a license agreement with NKMAX.
• The company issued Senior Convertible Notes and SPA Warrants to NKMAX.
• The company has a working capital loan facility with a related party.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and potential for dilution.
• Employees may be affected by potential layoffs or changes in the company's operations.
• Customers and patients may experience delays or disruptions in the development and availability of therapies.
• Suppliers and creditors may face uncertainty regarding payment and future business relationships.

Next Steps

• Advance clinical development of SNK01 in AD and PD.
• Continue the Phase I trial with SNK02 in refractory solid tumors.
• Evaluate expansion into other neurodegenerative diseases.
• Accelerate development in oncology through strategic collaborations.
• Continue investment in manufacturing technology.

Key Dates

Keywords

NK cell therapy, SNK cells, Alzheimer's disease, Parkinson's disease, Oncology, Biotechnology, Cell therapy, Clinical trials, Manufacturing, Merger, Financials, Intellectual property